Uncategorized

AstraZeneca, Ionis’ Wainua woes send waves across ATTR-CM space

Published

on

The failure of AstraZeneca and Ionis’ Wainua in a late-stage study of ATTR-CM casts doubt on Alnylam’s next-generation candidate but is good news for others in the space, including BridgeBio and Intellia Therapeutics.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version